EnteroMedics Inc., a company out of St. Paul, Minnesota, won European approval to market the company’s electrical vagal nerve stimulator for obesity control. The system blocks signals sent from the stomach to the brain, effectively relieving the sensation of hunger.
More about the vagal blocking therapy from the company:
EnteroMedics developed VBLOC™vagal blocking therapy to offer bariatric surgeons and their patients a less invasive alternative to existing surgical weight loss procedures that may present significant risks and alter digestive system anatomy, lifestyle and food choices. VBLOC Therapy is delivered via the Maestro™ System through laparoscopically implanted leads to intermittently block the vagus nerves using high-frequency, low-energy electrical impulses. VBLOC Therapy is designed to target the multiple digestive functions under control of the vagus nerves and to affect the perception of hunger and fullness. Preliminary results from the feasibility study conducted outside the U.S., which includes 38 patients, indicate that the Maestro System may provide durable and ongoing weight-loss for people with obesity. Follow up data show excess weight loss, or EWL, of 37.6% in 9 patients at 18 months of VBLOC Therapy and 28.1% in 17 patients at 12 months of therapy. To date, no deaths or unanticipated adverse device events have been reported.
Press release: EnteroMedics Receives CE Mark Certification for the Maestro System for Obesity Therapy
Flashbacks: Vagal BLocking for Obesity Control; Vagal Electrical Nerve Stimulation Helps With Weight Loss in Clinical Trial